The Changing Landscape of IBD: Emerging Concepts in Patient Management

By Raymond Cross, MD, MS and Gary Lichtenstein, MD

In the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of the inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn’s disease. Current biologic therapy with tumor necrosis factor inhibitors and anti-integrins has improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy. As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms. Geared to the needs of gastroenterologists, this IBD eHealth program includes an update on patient assessment and treat-to-target goals, as well as a review of best practices in shared decision-making in treatment decisions for induction and maintenance of remission. In addition, the immunopathogenesis of IBD is discussed in the context of current and emerging targeted therapies for moderate to severe disease.

• Language: English
• Publisher: Integritas Communications
• Release date: Dec 31, 2018
• ISBN: 9780998419435

Book preview

Preamble

Faculty

Raymond K. Cross, MD, MS

Professor of Medicine​

Director, Inflammatory Bowel Disease Program​

University of Maryland School of Medicine​

Co-Director, Digestive Health Center​

University of Maryland Medical Center​

Baltimore, Maryland

Dr. Raymond K. Cross is a board-certified Gastroenterologist and Professor of Medicine, Division of Gastroenterology and Hepatology, at the University of Maryland School of Medicine in Baltimore, Maryland. He also serves as Director of the Inflammatory Bowel Disease Program at the University of Maryland School of Medicine in Baltimore (UMB) and is Co-Director of the Digestive Health Center at the University of Maryland Medical Center in Baltimore.

Dr. Cross is a Fellow of the American Gastroenterological Association and a member of the American College of Gastroenterology and Crohn’s and Colitis Foundation of America (CCFA). He is the past Chair of the Patient Education Committee and current Chair of the Clinical Awards Committee of the CCFA. He is also a member of the Mission Committee of the Maryland and Delaware Chapter of the CCFA.

Dr. Cross received his undergraduate degree from Washington and Jefferson College in Washington, Pennsylvania, and his medical degree from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. He completed his postgraduate training in Internal Medicine at the University of Maryland and Baltimore VA Medical Centers in Baltimore, Maryland, where he was chosen as Chief Resident. He performed his Gastroenterology fellowship also at the University of Maryland and Baltimore VA Medical Centers in Baltimore. In addition, Dr. Cross has obtained a Master of Science degree in Clinical Research at the University of Maryland School of Medicine, Department of Epidemiology and Preventive Medicine, in Baltimore.

Gary R. Lichtenstein, MD

Professor of Medicine​

Director, Center for Inflammatory Bowel Diseases​

The Raymond and Ruth Perelman School of Medicine ​

University of Pennsylvania​

Hospital of the University of Pennsylvania​

Gastroenterology Division, Department of Internal Medicine​

Perelman Center for Advanced Medicine​

Philadelphia, Pennsylvania

Dr. Gary R. Lichtenstein is the Director of the Inflammatory Bowel Disease Center and a Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania.

Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, New York, New York. He then completed his internship and residency in Internal Medicine at Duke University Medical Center, Durham, North Carolina, and a fellowship in Gastroenterology at the Hospital of the University of Pennsylvania School of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn's disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/ international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn's disease.

A Fellow of the American Gastroenterological Association, the American College of Physicians, and the American College of Gastroenterology, he has served as Medical Secretary for the American Board of Internal Medicine, Gastroenterology Section. He holds membership and committee positions in many professional societies at a national level, including the American Gastroenterological Association, where he has served as chair and vice-chair of the clinical practice committee and as vice-chair of the practice economics committee; the American Society for Gastrointestinal Endoscopy, where he has served on the committee on training; the American College of Gastroenterology, where he